Several growth factors and cytokines, including EGF, are known to induce tyrosine phosphorylation of Signal Regulatory Proteins (SIRPs). Consistent with the idea that increased phosphorylation activates SIRP function, we overexpressed human SIRPa1 in U87MG glioblastoma cells in order to examine how SIRPa1 modulates EGFR signaling pathways. Endogenous EGFR proteins are overexpressed in U87MG cells and these cells exhibit survival and motility phenotypes that are in¯uenced by EGFR kinase activity. Overexpression of the SIRPa1 cDNA diminished EGF-induced phosphoinositide-3-OH kinase (PI3-K) activation in U87MG cells. Reduced EGFstimulated activation of PI3-K was mediated by interactions between carboxyl terminus of SIRPa1 and the Src homology-2 (SH2)-containing phosphotyrosine phosphatase, SHP2. SIRPa1 overexpression also reduced the EGF-induced association between SHP2 and the p85 regulatory subunit of PI3-K. Inhibition of transformation and enhanced apoptosis following g-irradiation were observed in SIRPa1-overexpressing U87MG cells, and enhanced apoptosis was associated with reduced levels of bcl-x L protein. Furthermore, SIRPa1-overexpressing U87MG cells displayed reduced cell migration and cell spreading that was mediated by association between SIRPa1 and SHP2. However, SIRPa1-overexpressing U87MG clonal derivatives exhibited no dierences in cell growth or levels of mitogen-activated protein kinase (MAPK) activation. These data reveal a pathway that negatively regulates EGFR-induced PI3-K activation in glioblastoma cells and involves interactions between SHP2 and tyrosine phosphorylated SIRPa1. These results also suggest that negative regulation of PI3-K pathway activation by the SIRP family of transmembrane receptors may diminish EGFR-mediated motility and survival
Introduction
Observations in hematopoietic cells showing that signaling from receptor tyrosine kinases (RTKs) could be attenuated by association with phosphotyrosine phosphatases led to the identi®cation of distinct families of inhibitory receptors (reviewed in Cambier, 1997; Coggeshall, 1999) . Most of the inhibitory receptors are monomeric proteins that contain multiple immunoglobin super-family (IgSF) domains in their extracellular regions (Cambier, 1997) . A consensus cytoplasmic sequence found in these inhibitory receptors, referred to as the immunoreceptor tyrosine-based inhibitory motif or ITIM, binds to the SH2 domaincontaining phosphotyrosine phosphatases (PTPs) SHP1 and SHP2. More recent eorts (Fujioka et al., 1996; Ohnishi et al., 1996; Kharitonenkov et al., 1997) led to the isolation and cloning of new inhibitory receptors in neurons and epithelial cells based on their binding to SHP2. Signal-Regulatory Proteins [SIRPs (Kharitonenkov et al., 1997) ; murine homolog SHPS-1, or SHP substrate 1 (Fujioka et al., 1996) ], a family of membrane glycoproteins and putative substrates of the SHP1 and SHP2 phosphatases, are unique members of the inhibitory receptor family whose members are ubiquitously expressed. While expression of SHP1 is restricted to hematopoietic cells, the distribution of SHP2 (previously called SH-PTP2, PTP2C, PTP1D, SHPTP3, and Syp) is similarly widely expressed (Ahmad et al., 1993; Feng and Pawson, 1994) .
The ITIM motif, (V/I/T)x Yxx(V/L) (where V is valine, I is isoleucine, T is threonine, L is leucine, Y is tyrosine, and X is any residue) was identi®ed by sequence analysis of inhibitory receptors originally identi®ed in hematopoietic cells (D'Ambrosio et al., 1995; Daeron et al., 1995) . Phosphorylation of the tyrosine in ITIM triggers binding and activation of SHP1 and SHP2 and, in some cases, the phosphatidylinositol (3,4,5)P 3 5' inositol phosphatase, SHIP (Cambier, 1997; Coggeshall, 1999) . Mutation of the I/V position disrupts binding of SHP1 and SHP2 (Vely et al., 1997) . In many systems, the binding of SH2 domain-containing phosphatases appears to be critical to the function of inhibitory receptors and PTPs may represent the eectors of inhibitory receptors. It is likely that distinct dierences in the primary sequence Oncogene (2000) 19, 3999 ± 4010 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc surrounding the phosphotyrosine residue underlies dierential recruitment of SH2 domain-containing proteins between positive and negative signaling receptors (Cambier, 1997; Coggeshall, 1999) . Investigation of mechanisms of PTP binding to ITIM motifs may shed light on PTP functional regulation, since little is known regarding the recruitment and activation of PTPs under physiologic conditions. SIRP/SHPS-1 proteins are tyrosine phosphorylated in response to EGF and insulin, and were originally identi®ed in anti-SHP2 immunoprecipitates (Fujioka et al., 1996; Kharitonenkov et al., 1997; Takada et al., 1998) . Integrin signaling also increases SHPS-1 tyrosine phosphorylation and SHP2 binding , suggesting that SIRP/SHPS-1 proteins modulate cell signaling in response to both soluble growth factors and cell adhesion. Collectively, these ®ndings suggest that multiple RTK-induced pathways may be downstream targets of SIRP. SIRP has been experimentally shown to modulate signaling of many RTKs, including the insulin receptor and the Epidermal Growth Factor Receptor (EGFR) (Kharitonenkov et al., 1997; Takada et al., 1998) . SIRP tyrosine phosphorylation and subsequent recruitment of SHP2 to the plasma membrane have been shown to be related to SIRP functional regulation of RTK signaling (Cambier, 1997; Kharitonenkov et al., 1997) . Many isoforms of human SIRP and murine SHPS-1 proteins have been identi®ed and multiple transcripts of SIRP and SHPS-1 genes have been observed in many tissues, particularly in neural cells (Fujioka et al., 1996; Kharitonenkov et al., 1997; Yamao et al., 1997; Veillette et al., 1998; Jiang et al., 1999) . Two subtypes of the SIRP protein family, containing at least 15 members, have been con®rmed (Kharitonenkov et al., 1997) . SIRPa proteins are distinguished from SIRPb forms by the presence of an endodomain containing ITIMs (Veillette et al., 1998) , which bind SHP2 (Kharitonenkov et al., 1997; Veillette et al., 1998) .
Mechanisms by which ITIM-containing receptors such as SIRP mediate their inhibitory eects, and the role of the SIRP/SHP2 complex in this process, have not been well characterized. SIRP/SHPS-1 receptors have been shown to positively or negatively regulate MAPK pathways following stimulation of many dierent receptors (Kharitonenkov et al., 1997; Takada et al., 1998) . SIRPa1 overexpression in NIH3T3 cells inhibited DNA synthesis and MAPK phosphorylation following EGF or insulin stimulation (Kharitonenkov et al., 1997) . Genetic and biochemical studies have shown that SHP2 may positively regulate MAPK signaling in response to insulin, FGF, and EGF (Noguchi et al., 1994; Tang et al., 1995; Bennett et al., 1996; Saxton et al., 1997; Deb et al., 1998; Shi et al., 1998) , but attenuate MAPK activation following PDGF and neuregulin stimulation (Saxton et al., 1997; Tanowitz et al., 1999) . In other studies, increased SHPS-1/SHP2 complex formation resulting from overexpression of SHPS-1 potentiated the RAS-MAPK pathway in response to insulin or integrin stimulation (Oh et al., 1999 ). The precise mechanisms by which SIRP/ SHPS-1 proteins regulate MAPK signaling and other signaling pathways, and how the SIRP/SHP2 complex alters RTK-induced cell signals and phenotype, have therefore not been established.
ErbB family kinases are overexpressed and/or mutated in a number of human tumors, including human glioblastomas in which erbB1/EGFR signaling pathways are deregulated (Nishikawa et al., 1994; Nagane et al., 1996; Huang et al., 1997; O'Rourke et al., 1997a,b; 1998a) . Mechanisms of attenuating EGFR signaling in glioblastoma cells have not been completely de®ned. Since tyrosine phosphorylated SIRPa1 has been shown to inhibit EGF-stimulated responses, including DNA synthesis (Kharitonenkov et al., 1997) , analysis of SIRP protein function may also yield insight into physiologic mechanisms of erbB1/ EGFR signaling inhibition. Biochemical characterization of erbB1/EGFR inhibitory events may lead to application of receptor-based therapies for many erbBexpressing human tumors, including human glioblastomas, the most malignant and most common adult human brain tumor.
In this study, we evaluated modulation of erbB1/ EGFR signaling pathways and phenotype by ectopically overexpressed SIRP proteins in human glioblastoma cells. We have used the human glioblastoma U87MG cell line as a model system to characterize EGFR-mediated transforming and survival phenotypes (Nishikawa et al., 1994; Nagane et al., 1996; Huang et al., 1997; O'Rourke et al., 1997a O'Rourke et al., , 1998a . Independent studies of the PTEN tumor suppressor protein have shown that deregulated PI3-K pathway activation alters glioblastoma survival, transformation, motility and adhesion (Furnari et al., 1997 (Furnari et al., , 1998 Tamura et al., 1998; Wick et al., 1999) . In this study, we demonstrate new functional roles for tyrosine phosphorylated human SIRPa1 proteins in modulating EGFR signaling pathways and phenotype of human glioblastoma cells. SIRPa1 negatively regulates EGFinduced PI3-K activation and leads to reduced transformation, reduced cell migration and cell spreading, and enhanced apoptosis following DNA damage in EGFR-containing human glioblastoma cells.
Results

SIRPa1 modulation of EGFR-mediated cell growth and transformation in human glioblastoma cells
EGF-induced phosphorylation of the SIRP/SHPS-1 receptor Tanowitz et al., 1999; suggested that SIRP/SHPS-1 proteins may modulate EGFR signaling pathways. Inhibition of EGF-and insulin-induced DNA synthesis and MAPK phosphorylation was observed in NIH3T3 cells overexpressing SIRPa1 (Kharitonenkov et al., 1997) .
Our previous work utilized a trans-dominant mutant receptor derived from p185 neu that inhibits EGFR kinase activity to show that EGFR signaling determines transforming and apoptotic phenotypes in U87MG glioblastoma cells (O'Rourke et al., 1997a; 1998a,b) . In order to investigate the relationship between SIRP function and EGFR signaling pathways, we overexpressed the SIRPa1 cDNA in U87MG cells, which contain high endogenous levels of EGFR, but no other detectable erbB family proteins (O'Rourke et al., 1997a) . Stable U87MG clones expressing elevated amounts of the SIRPa1 protein were inhibited 65% in the formation of morphologically transformed foci, as compared to clones expressing vector without insert (mean number of foci+s.d.: U87/pIRES 31+1.4; U87/ SIRPa1 11+2.8; data con®rmed in three independent experiments) ( Figure 1a) . Con®rmation of ectopic SIRPa1 expression was con®rmed by Western blotting (Figure 5a ). These data were reproduced in other SIRPa1-overexpressing subclones. Therefore, SIRPa1 inhibited the transformed phenotype in human glioblastoma cells.
Interestingly, cell growth after 48 h, as determined by the MTT assay, was unaected by overexpression of SIRPa1 in U87MG cells (Figure 1b) . Dierences in cell growth were also not observed in SIRPa1-overexpressing cells in full growth media for up to 7 days (data not shown). These data suggest that inhibition of transformation mediated by SIRPa1 is not related to a reduction in cell growth in vitro in full growth media. The SIRPa pathway(s) in glial cells may be more relevant to transformation characteristics than mitogenic proliferation.
SIRPa1 overexpression enhances DNA damage-induced apoptosis in human glioblastoma cells
The role of SIRP proteins in cell survival has not been evaluated. We previously showed that inhibition of erbB signaling pathways in human astrocytoma and glioblastoma cells enhanced apoptosis after irradiationinduced DNA damage (O'Rourke et al., 1998b) . Prolonged serum deprivation (96 h) did not induce apoptosis in transformed U87MG parental cells or U87/SIRPa1 subclones (data not shown), supporting previous observations in glioma cells (O'Rourke et al., 1998b) . However, overexpression of the SIRPa1 cDNA conferred increased sensitivity to apoptosis following girradiation as determined by an examination of nuclear morphology following staining with 4',6-Diamidino-2-phenylindole dihydrochloride hydrate (DAPI) (O'Rourke et al., 1998b) . For a positive control in the analysis of apoptosis, we used U87/T691 cells engineered to express a kinase-de®cient mutant p185 neu receptor that display increased sensitivity to irradiation-induced cell death (O'Rourke et al., 1998b 3a) . Interestingly, apoptosis of irradiated U87/ SIRPa1 cells was not enhanced by serum deprivation (data not shown), suggesting the activation of a pathway that is serum-independent.
Expression of a mutant EGFR oncoprotein in U87MG cells leads to elevated bcl-X L protein levels and resistance to apoptotic cell death triggered by exposure to chemotherapy (Nagane et al., 1998) . Since EGFR stimulation modulates SIRP tyrosine phosphorylation, and SIRPa1 expression can diminish EGFRmediated transformation in U87MG cells, we investigated the hypothesis that apoptosis occurring in SIRPa1-overexpressing cells may result from reduced levels of the bcl-x L protein. Bcl-X L was induced following g-irradiation in U87MG-derived cells ( Figure  3d ). Interestingly, basal and radiation-induced levels of bcl-X L protein were reduced in U87/SIRPa1 cells relative to controls (Figure 3d ). Bcl-X L levels returned to baseline 72 h following irradiation in U87/SIRPa1 cells, while cells expressing vector without insert showed sustained elevation in bcl-X L protein levels 24 ± 72 h following g-irradiation ( Figure 3d ). Modulation of Bcl-X L protein levels has also been shown to in¯uence sensitivity to apoptosis in EGFR-containing keratinocytes exposed to cell death signals (Rodeck et al., 1997) .
Overexpressed SIRPa1 does not modulate MAPK activities in glioblastoma cells
EGFR-dependent signaling and phenotypes in glioblastoma cells have been characterized by our laboratory (Qian et al., 1996; O'Rourke et al., 1997a O'Rourke et al., , 1998a Wu et al., 1999) and others (Nishikawa et al., Figure 1 SIRPa1 inhibits EGFR-mediated transformation of U87MG human glioblastoma cells but does not aect cell proliferation. (a) Transforming eciency of SIRPa1-overexpressing U87MG-derived subclones. Two hundred U87MG-derived cells were plated with 10 4 NR6 cells (Pruss and Herschman, 1977) and grown in 5% FBS-DMEM for 14 days. Foci (mean+s.d.) were then stained and quantitated based on triplicate dishes for each cell line. These data were con®rmed by three independent experiments. (b) Cell growth at 48 h following overnight attachment in 10% FBS-DMEM was indistinguishable between U87/ pIRES and U87/SIRPa1 cells. Results (mean+s.d.) of absorbance at 570 nm as determined by an ELISA reader are displayed for two cell concentrations and were in the linear range for this cell type (Hansen et al., 1989) . Results were con®rmed in three independent experiments 1994; Nagane et al., 1996 Nagane et al., , 1988 Huang et al., 1997) . Several groups have reported a modulation of MAPK activities by SIRP or SHPS-1 (see Introduction). Therefore, one mechanism by which SIRP inhibits EGFR-mediated signaling may be through modulation of MAPK activities. Unexpectedly, in vitro kinase assays showed that EGF-induced activation of extracellular signal-regulated kinase (ERK)-1, ERK-2, and c-jun amino-terminal kinase (JNK) were comparable in human glioblastoma cells stably expressing SIRPa1 when compared to cells expressing vector without insert ( Figure 4) . Notably, basal ERK activities between U87MG parental and U87/SIRPa1 subclones were comparable (data not shown).
Ectopically expressed SIRPa1 negatively regulates EGF-induced PI3-K activation through carboxyl terminal interactions with SHP2
In order to more precisely de®ne the mechanism by which SIRPa1 modulates transforming and apoptotic pathways in EGFR-containing glioblastoma cells, we examined EGF-induced PI3-K activity in U87MG cells ( Figure 5 ). U87MG cells overexpressing wild-type SIRPa1 (U87/SIRPa1) (Figure 5a ) exhibited reduced EGF-induced PI3-K activity in anti-phosphotyrosine (anti-pTyr) immunoprecipitates when compared to U87MG cells containing vector alone (U87/pIRES) ( Figure 5b, lanes 2, 4) . Basal PI3-K activities in these U87MG derivatives were comparable. In order to de®ne whether SIRPa1 attenuates EGF-induced PI3-K activation by binding SHP2, we utilized a carboxyl terminal SIRPa1 mutant (SIRPa1-4Y) in which four carboxyl terminal tyrosines have been mutated to phenylalanine, making this mutant incapable of binding to SHP2 (Kharitonenkov et al., 1997) and seen below, Figure 6a,c) . Cells overexpressing the SIRPa1-4Y mutant (U87/SIRPa1-4Y) displayed EGFinduced PI3-K activation that was comparable to cells containing empty vector alone (Figure 5b , lanes 1, 2; 5, 6), indicating that a SIRP/SHP2 complex reduces EGF-induced PI3-K activity. These data were reproduced in multiple SIRPa1-and SIRPa1-4Y-overexpressing subclones.
SHP2 immunoprecipitates have been shown to contain PI3-K activity (Takahashi et al., 1999) . In order to examine SIRP modulation of PI3-K activity directly associated with SHP2, we assayed induced PI3-K activity contained in anti-SHP2 immunoprecipitations. In our studies, anti-SHP2 immunocomplexes contained signi®cant amounts of PI3-K activity ( Figure  5c ), suggesting that SHP2 plays an important role in regulating EGF-induced PI3-K activation in human glioblastoma cells. Interestingly, anti-SHP2 immunoprecipitates displayed the same pattern of PI3-K activation in these U87MG subclones as anti-phosphotyrosine immunocomplexes (Figure 5b,c) . Moreover, anti-EGFR and anti-p85 (PI3-K) immunoprecipitations also displayed the same trends observed with anti-pTyr and anti-SHP2 immunoprecipitations (not shown). It is possible that SHP2 may contain the majority of PI3-K activity in EGF-stimulated glioblastoma cells, although there may be dierences in anity for tyrosine phosphorylated substrates between anti-SHP2 and anti-phosphotyrosine antibodies. Genetic studies have shown that SHP2 functions as a positive regulator of EGFR signaling and that EGFR/SHP2 interactions contribute to PI3-K modulation in mammalian cells (Qu et al., 1999) . Since the SIRPa1-4Y mutant protein cannot bind SHP2 (Figure 6 ) (Kharitonenkov et al., 1997), these data indicate that SIRPa1 negatively regulates EGF-induced PI3-K activation through carboxyl terminal interactions that include association with the SHP2 phosphatase.
Tyrosine phosphorylated SIRPa1 binds SHP2 and reduces SHP2/p85 association in human glioblastoma cells Many studies have since con®rmed the observation that the SIRP receptor binds SHP2 in mammalian cells, and that this event is required for SIRPa function (Kharitonenkov et al., 1997) . In SHP2 immunocomplexes from U87MG subclones, overexpressed SIRPa1 was tyrosine phosphorylated and associated with SHP2 constitutively (Figure 6a,c, lane 3) . EGF treatment increased the amount of tyrosine phosphorylated SIRP and total SIRP bound to SHP2 (Figure 6a,c, lanes 3,  4) . Since tyrosine phosphorylation has been linked to SIRPa1 function, U87/SIRPa1 subclones therefore contain functional SIRP in the absence of EGF. Despite the level of ectopically expressed SIRPa1-4Y in U87/SIRPa1-4Y cells (Figure 5a ), anti-SHP2 immunoprecipitates did not contain SIRPa1-4Y with or without EGF stimulation (Figure 6c, lanes 5, 6) . These results are consistent with data indicating that SIRPa1 binds SHP2 through carboxyl terminal sites mutated in the SIRPa1-4Y protein.
Recent studies have noted the association between SHP2 and p85 in certain cell types, including an association induced in PC12 cells by NGF (Okada et al., 1996) and in cortical neurons by BDNF (Okada et al., 1996; Yamada et al., 1999) . EGF induced the Figure 2 SIRPa1 enhances apoptosis following gamma-irradiation in U87MG human glioblastoma cells. Mean+s.d. of counts derived from two independent observers are presented as a percentage. Over 600 cells were counted in multiple ®elds for each sample after staining with 4',6-Diamidino-2-phenylindole dihydrochloride hydrate (DAPI) and assessing the morphologic appearance of apoptosis at 48 ± 72 h. At 72 h following irradiation (10 Gy, 6 min), levels of apoptosis were signi®cantly (*) higher in U87/SIRPa1 cells (P5.05) and in U87/T691 cells (P5.005) than in control U87/pIRES cells. Results were con®rmed in three independent experiments association between endogenous SHP2 and the p85 regulatory subunit of PI3-kinase in U87MG cells expressing vector without insert (Figure 6b, lanes 1,  2) . In U87MG/SIRPa1 cells, EGF-induced association between SHP2 and p85 was diminished (Figure 6b,  lanes 3, 4) . EGF-induced association between p85 and SHP2 was observed in cells expressing the mutant SIRPa1-4Y endodomain (Figure 6b, lanes 5, 6) , suggesting that tyrosine phosphorylated SIRPa1 must bind SHP2 to modulate PI3-K activation (Figure 5b,c) . One possibility is that functional SIRPa1 sequesters SHP2 from p85. Given the two SH2 domains and phosphotyrosine phosphatase activity in SHP2, along with the number of signaling pathways modulated by SHP2, SHP2-mediated modulation of PI3-K activation is likely to be complex. These data suggest a novel regulatory mechanism of EGF-induced PI3-K activation whereby functional SIRPa proteins may negatively modulate PI3-K activation by inhibiting an EGFinducible SHP2/p85 association.
SIRPa1 regulates glioblastoma cell migration and cell spreading through SHP2
Immortalized ®broblasts derived from a transgenic mouse in which the NH2-terminal SH2 site in SHP2 had been deleted exhibited phenotypic defects in cell migration and cell spreading, suggesting that SHP2 interactions may regulate attachment to cell ± matrix interactions and cell migration in particular cell types (Yu et al., 1998) . More recent reports have illustrated that SHP2 may be a general regulator of cell motility and integrin signaling (Yu et al., 1998; Oh et al., 1999) and that cooperative activity between SHP2 and Fak may be important for this regulation (Manes et al., 1999) .
We next examined the speci®c role of the SIRPa1 carboxyl terminus in migration and spreading of human glioblastoma cells by using glioblastoma clones overexpressing wild-type or mutated SIRPa1. U87MG cells have a characteristic morphology and have been and U87/SIRPa1 cells were immunoprecipitated by antibodies preferentially reactive with both phosphorylated and nonphosphorylated ERK1 (lanes 1,2), ERK2 (lanes 3,4) and JNK1 (lanes 5,6) forms and were then incubated with either MBP (lanes 1 ± 4) or GST-jun (lanes 5,6) following EGF treatment (5 min, 100 ng/ ml, 378C). In vitro kinase activities for ERK1, ERK2, and JNK1 were comparable between U87/pIRES and U87/SIRPa1 stably transfected subclones used for studies of cell migration and cell spreading modulated by the PTEN phosphatase mutated in many human glial tumors (Tamura et al., 1998) . U87MG cells expressing either empty vector, SIRPa1 or SIRPa1-4Y were assessed for migration on ®bronectin. Notably SIRP proteins are constitutively phosphorylated in the U87MG subclones used for these experiments (Figure 6a ). U87/SIRPa1 cells containing wild-type SIRPa1 exhibited a reduced rate of cell migration between 2 ± 4 h after plating when compared to U87MG clones expressing either empty vector or SIRPa1-4Y (Figure 7) . Therefore, reduced glioblastoma cell motility was observed in cells expressing elevated levels of tyrosine phosphorylated SIRPa1.
To examine the spreading eciency of glioblastoma cells expressing wild-type or mutated SIRPa1, we collected U87MG subclones in serum-free DMEM and plated cells on ®bronectin-coated cell culture dishes. Figure 8a illustrates the progression of cell spreading following plating of the U87MG subclones. U87MG cells were well-suited for this analysis since they displayed a relatively homogeneous morphology immediately after plating. U87MG cells containing empty vector (U87/pIRES cells) initiated spreading at 10 min and greater than 50% of cells had attained ā at morphology at 25 min. By 60 min, greater than 90% of cells were well-extended and displayed a¯at morphology. Cell spreading was reduced by overexpression and tyrosine phosphorylation of wild-type SIRPa1 (Figure 8a,b) . Fewer U87/SIRPa1 cells had initiated spreading and more appeared smaller at 10 min. In contrast to U87/pIRES cells, the majority of U87/SIRPa1 cells stayed round at 25 min. Notably, a signi®cant amount of U87/SIRPa1 cells were not well-extended at 60 min. SIRPa1-4Y-expressing cells exhibited no apparent morphological dierences from control cells. These data were reproduced in multiple SIRPa1-and SIRPa1-4Y-overexpressing subclones. Therefore, the tyrosine phosphorylated SIRPa1 carboxyl terminus reduces cell migration and cell spreading. Since the SIRPa1-4Y mutant receptor is not tyrosine phosphorylated and does not associate with SHP2 ( Figure 6 ), these data suggest that functional phosphorylated SIRPa1 negatively regulates cell migration and cell spreading through carboxyl terminal interactions with SH2 domains in SHP2. These data were reproduced in independent experiments using additional subclones.
Discussion
In this study, we have demonstrated several new functions for the SIRP transmembrane receptor that may begin to shed light on the mechanism by which ITIM-containing inhibitory receptors convey biological signals. In glioblastoma cells, SIRP proteins negatively regulated EGF-induced PI3-K activation by carboxyl terminal interactions with SH2 domains in SHP2. Our studies also indicate that tyrosine phosphorylated SIRPa1 inhibits an inducible association between SHP2 and the p85 regulatory subunit of PI3-K, which may interfere with activation of the p85/p110 PI3-K heterodimer. Modulation of an association between SHP2 and the p85 regulatory subunit is consistent with the role of SIRPa1 in regulating PI3-K activation. Our results support previous studies indicating a critical role for PI3-K activation in transformation, motility and survival of mammalian cells, particularly human glioblastoma cells. Phenotypic consequences of SIRP activation and diminished SHP2/p85 interaction include reduced PI3-K activation, inhibition of transformation, reduced cell migration and cell spreading and enhanced apoptosis following DNA damage. SIRP modulation of DNA damage-induced apoptosis appears to involve regulation of bcl-X L total protein levels, a ®nding that has been observed by others following deregulation of EGFR signaling pathways in glioblastoma cells (Nagane et al., 1998 ). These studies demonstrate for the ®rst time that tyrosine phosphorylated SIRP proteins can attenuate PI3-K activation following stimulation of EGFR. In our studies, EGF induced signi®cant PI3-K activity in human glioblastoma cells in both antiphosphotyrosine and anti-SHP2 immunocomplexes. These results suggest that much of the EGF-induced PI3-K activation in glioblastoma cells may occur in a complex that contains SHP2. The precise role of SHP2 in regulating the PI3-K pathway in astrocytoma cells has not been resolved. Notably, anti-p85 and anti-SHP2 immunoprecipitations revealed the same trends of PI3-K activities as anti-pTyr immune complexes. Biochemical studies using chimeric murine ES cells containing mutant SHP2 alleles have shown that SHP2 is a critical mediator of EGFR signaling and that combined disruption of EGFR and SHP2 function modulates EGF-induced PI3-K activation (Qu et al., 1999) . Our data suggest that negative PI3-K regulation requires the formation of a SHP2/SIRP complex and that this complex may be an important mechanism of attenuating EGFR-induced PI3-K signaling. SHP2/ SIRP regulation of PI3-K activation is supported by our data demonstrating that SHP2/SIRP interactions alter glioblastoma spreading and migration, two phenotypes which appear to be more related to PI3-K signaling than MAPK signaling. Our recent experiments indicate a similar diminution of Akt/ PKB phosphorylation by the functional SHP2/SIRP complex, supporting our results on PI3-K activation. SHP2/SIRP complex formation may serve to recruit and modulate PI3-K activity at the plasma membrane and may therefore represent a distinct mechanism of modulating the PI3-K pathway following stimulation of EGFR in glioblastoma cells.
SHP2 has been reported to associate inducibly with p85 in PC12 cells and primary neurons (Okada et al., 1996; Yamada et al., 1999) and in hematopoietic cells (Craddock and Welham, 1997; Gesbert et al., 1998) and to bind inducibly the lipid phosphatase SHIP, in addition to unknown tyrosine phosphorylated proteins p100 and p120 in hematopoietic cells (Carlberg and Rohrschneider, 1997; Zhang and Broxmeyer, 1999) . In human skin ®broblasts, distinct complexes involving SHP2, p85, and uncharacterized tyrosine phosphorylated proteins p115 and p105, but not including EGFR or erbB3, were found to speci®cally regulate EGFinduced PI3-K activity (Takahashi et al., 1999) . It is possible that the identi®ed 105 ± 115 kDa proteins in these studies represent the Gab1 (Shi et al., 2000) or Gab2 adaptor proteins . However, complexes involving SHP2 and p85 may also contain SIRP/SHPS-1, since numerous SIRP/SHPS-1 proteins of 90 ± 120 kDa have been identi®ed in dierent mammalian cell types, in part due tissue-speci®c glycosylation dierences (Kharitonenkov et al., 1997; Veillette et al., 1998) .
Cumulatively, the data suggest that a complex containing SHP2 and SIRP, and possibly other adaptor/eector proteins, modulates cell signaling following stimulation of EGFR. However, a MAPKindependent function for SIRP/SHPS-1 proteins distinct from that previously reported (Kharitonenkov et Figure 6 SIRPa1 inhibits inducible binding of SHP2 to p85 regulatory subunit in glioblastoma cells. U87/pIRES, U87/ SIRPa1, and U87/SIRPa1-4Y cells were serum-starved for 24 h, followed by treatment with or without EGF (50 ng/ml for 5 min). Whole cell extracts were then immunoprecipitated by an antibody reactive with SHP2 and analysed by 8% SDS ± PAGE according to Materials and methods. For a ± d, immunoblotting of SHP2 immunocomplexes was performed with the indicated antibodies and signals were visualized with the ECL detection system Figure 7 SIRPa1 reduces glioblastoma cell migration through an interaction with SHP2. To measure cell motility, U87MG clones expressing either empty vector, SIRPa1, or SIRPa1-4Y were added to the upper chamber separated by a 8 mm porous membrane in a 6.5 mm Transwell chamber. The cells were incubated at 378C for the indicated times, and allowed to migrate through the membrane into the lower side which was coated with ®bronectin. Migrated cells on the lower side of the membrane were then counted. The data represent mean+s.d. of a representative experiment with all samples performed in triplicate. These data were reproduced in three additional experiments al., 1997; Takada et al., 1998) is suggested by our data in glioblastoma cells. Our data indicate that inhibition of transformation and reduced survival following DNA damage observed in SIRPa1-overexpressing human glioblastoma cells are not mediated by alterations in basal or EGF-induced MAPK activities. Similarly, SIRP activation does not appear to modulate mitogenic pathways in glioblastoma cells. Cell context may be critical for SIRP signaling. In COS7 cells we have been unable to document the association between SHP2 and p85 that we have consistently demonstrated in U87MG glioblastoma cells. Given that the association between SHP2 and p85 can only be documented in some cell types, e.g. glioblastoma cells, it is not surprising that SIRP may preferentially regulate PI3-K signaling in some cells and MAPK activation in others. SIRP appears to negatively modulate MAPK signaling in NIH3T3 cells (Kharitonenkov et al., 1997) , but diminish PI3-K activation in astrocytes.
Our data indicate that SIRP/SHP2 complexes modulate extracellular matrix-induced signals that may in¯uence eciency of cell transformation and cell survival. Moreover, our ®ndings support studies indicating that PI3-K signaling pathways, rather than MAPK activation, are critical for cell motility and cell survival (Manes et al., 1999; Tan et al., 1999) , both of which may contribute to epithelial cell transformation. Cell adhesion is critical for maintaining the integrity and topography of tissues. Proper cell adhesion requires cell ± matrix adhesion and cell ± cell adhesion. Cell adhesion molecules induce signals that in¯uence cell proliferation, dierentiation, motility and survival (Gumbiner, 1996) . Cell spreading has been shown to be closely linked to cell survival (Re et al., 1994; Chen et al., 1997) . Recent evidence has indicated that HRG-binduced cell ± cell adhesion (aggregation) of MCF-7 human breast cancer cells is sensitive to the PI3-K inhibitors wortmannin and LY294002, but not to the MEK1 inhibitor PD98059 (Tan et al., 1999) . The active signaling complex mediating this phenotype appeared to be an erbB2/erbB3 heterodimer containing more inducibly bound p85 in response to HRG-b. Others have shown that inhibition of HRG-stimulated PI3-K activation, cytoskeletal reorganization and cell migration of MCF-7 cells occurs independently of extracellular signal-regulated kinases (Adam et al., 1998) . Moreover, PD-98059 has been reported to have only a marginal eect on migration of MCF-7 breast cancer cells (Manes et al., 1999) . Our data reveal that migration and spreading of glioblastoma cells were reduced by increased SIRP tyrosine phosphorylation and binding of SHP2 in cells that also displayed reduced EGFinduced PI3-K activation. Taken together, the data suggest that SIRP/SHP2 complexes may coordinate independent signals initiated by integrins and the EGF receptor that may converge on PI3-K.
Our data also reveal increased biochemical complexity in the regulation of cell motility by SHP2. Mouse ®broblasts de®cient in functional SHP2 showed defects in cell migration and spreading on ®bronectin (Yu et al., 1998) . However, expression of catalytically-inactive SHP2 in Rat-1 ®broblasts and CHO cells increased the rate of cell attachment to and spreading on ®bronectin (Inagaki et al., 2000) . Therefore, the mechanism by which SHP2 regulates cell motility is not clear and may require a highly complex coordination of signals that are related to cell context. Our studies indicate that binding of functional SIRPa1 to SHP2 is able to reduce motility of human glioblastoma cells. Motility-impaired glioblastoma subclones also displayed reduced inducible association of SHP2 with p85 and reduced PI3-K activation, suggesting that the SHP2/p85 association may be critical in positively regulating cell migration and spreading through activation of the PI3-K pathway. Expression of the DEGFR oncoprotein in ®broblasts leads to preferential activation of PI3-K rather than MAPK (Moscatello et al., 1996 (Moscatello et al., , 1998 . Furthermore, expression of the DEGFR oncoprotein in glioblastoma cells induces elevated constitutive PI3-K activity, enhanced SHP2/ p85 association and increased cell motility (C-J Wu and DM O'Rourke, unpublished observations).
It is interesting that functional restoration of the PTEN phosphatase into U87MG cells leads to reduced cell migration and cell spreading (Tamura et al., 1998) . PTEN negatively regulates an Akt/PKB survival pathway (Stambolic et al., 1998; Wu et al., 1998) and is mutated or lost in many high-grade glial tumors and established glioma cell lines, including U87MG cells (Li et al., 1997; Steck et al., 1997) . Akt/PKB is a PI3-K eector that becomes localized to sites of cell ± cell and cell ± matrix contact in epithelial cells in a PI3-Kdependent manner (Watton and Downward, 1999) . Reintroduction of PTEN into glioma cells has been reported to increase anoikis (Davies et al., 1998) , a process of programmed cell death undergone by epithelial cells upon detachment from the extracellular matrix. Moreover, functional PTEN also increases sensitivity to radiation-induced apoptosis (Wick et al., 1999) . One might speculate that functional SHP2/SIRP complexes regulate PI3-K mediated cell survival and motility pathway(s) modulated further downstream by the PTEN tumor suppressor. Understanding the biochemical consequences of SIRP/SHP2 interactions may lead to new strategies that interfere with cell motility and survival of EGFR-overexpressing glioblastoma cells, and perhaps other erbB-containing human cancer cells.
Materials and methods
Plasmid constructions
The human SIRPa1 and SIRPa1-4Y cDNAs contained in pRK5(RS) (Kharitonenkov et al., 1997) were modi®ed for eukaryotic expression. The pRK5(RS) plasmids were digested with NruI and XhoI and the fragments containing the SIRPa1 gene or its 4Y mutant gene were blunt-end ligated into the expression vector pIRES/Hyg (Clontech) previously linearized with BamHI and blunt-ended for ligation. Derivations of the carboxyl terminal-deleted p185 neu mutant receptor construct, T691stop, have been detailed previously (O'Rourke et al., 1997a) . Growth inhibitory properties of T691stop have been reported (O'Rourke et al., 1997a (O'Rourke et al., , 1998a .
Maintenance of cells and transfection procedures
Human U87MG glioblastoma cells were obtained from the American Type Tissue Collection (Rockville, MD, USA) and cultured in Dulbecco's modi®ed Eagle medium (DMEM) supplemented with 10% fetal bovine serum. For the analysis of SIRPa1 ectopic expression, U87MG cells were transfected either with empty vector (pIREShyg), pIRESHyg/SIRPa1, or mutant pIRES/SIRPa1-4Y plasmids using lipofectamine (Gibco-BRL, Gaithersburg, MD, USA) and were selected with 80 mg/ml of hygromycin (Roche Molecular Biochemicals, Indianapolis, IN, USA). Positive SIRPa1-or SIRPa1-4Y-expressing subclones (U87/SIRPa1 or U87/SIRPa1-4Y) were identi®ed by Western blotting using a polyclonal antibody reactive with SIRPa1. U87MG-derived clones expressing the vector without insert were designated U87/ pIRES cells. All the derived cells were maintained in DMEM containing hygromycin (35 mg/ml).
Immunoprecipitation, co-immunoprecipitation and Western blotting
Cells was seeded and allowed to attach overnight. After starvation for 24 h in DMEM containing 0.2% FBS, cells were treated with 50 ng/ml of EGF for 5 min at 378C. The cells were then washed twice with 10 mM sodium phosphate, pH 7.4, 150 mM NaCl, 1 mM Na 3 VO 4 and solublized in lysis buer (50 mM Tris-HCl, pH 7.5, 0.5% Triton X-100, 150 mM NaCl, 2 m MEGTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl¯uoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin).
Cell lysates were then subjected to centrifugation at 12 000 g for 15 min at 48C. After normalization of supernatants derived from untreated cells and treated cells by protein concentration with the Dc Protein Assay kit (BioRad, Hercules, CA, USA), 500 ± 1000 mg of each cell lysate was incubated with the indicated antibody (1 ± 3 mg) on ice for 2 h. Immune complexes were collected with Protein-A conjugated to Sepharose 4B (Sigma) and washed three times with 50 mM Tris, pH 7.5, 0.1% Triton X-100, 300 mM NaCl, 2 mM EGTA. The resulting immunoprecipitates were then subjected to SDS-polyacrylamide gel electrophoresis (PAGE) (6 ± 8%), and then transferred onto nitrocellulose membranes followed by Western blot analysis with the indicated antibodies using the ECL detection system (Amersham).
For Western blots evaluating Bcl-X L protein levels, cells were harvested at the indicated time points after irradiation (10 Gy, 6 min), and samples were boiled in lysis buer, as recommended by the Bcl-X L antibody producer's manual. After normalization by the Bio-Rad (Hercules, CA, USA) protein concentration assay, proteins were separated by 12% SDS ± PAGE.
MAP kinase and PI3-kinase immune complex kinase assays Cells deprived of serum for 24 h were treated with or without EGF (50 ng/ml) for 5 min. For MAP kinase assays, cells were lysed with RIPA buer (25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol, 1% Triton X-100, 0.5% sodium deoxycholate, 20 mM b-glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl¯uoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin). Protein concentrations were determined by the Dc Protein Assay kit (Bio-Rad). Equal amounts of proteins from cell extracts were immunoprecipitated with the indicated antibodies. After washing extensively, the immunocomplexes were then incubated with 50 ml of reaction buer [20 mM HEPES, 50 mM NaCl, 1 mM sodium orthovanadate, 20 mM MgCl 2 , 20 uM adenosine triphosphate (ATP), and 20 mM b-glycerophosphate (pH 7.4) containing 2 mCi of [g-32 P]ATP (NEN Life Science Products) and 2 mg of myelin basic protein (MBP) (Upstate Biotechnology Inc.) for the ERK kinase assays or 2 mg of c-Jun fusion protein (GST-jun) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for the JNK kinase assay. After incubation for 10 min at 308C, kinase reactions were terminated by the addition of 36 Laemmli sample buer. The samples were then resolved by SDS ± PAGE, and phosphorylated substrates were visualized by autoradiography.
PI3-kinase assays were carried out as previously described with slight modi®cations. Cells were lysed in Nonidet P-40 lysis buer (20 mM Tris-HCl(pH 7.4), 137 mM NaCl, 1 mM MgCl 2 , 10% glycerol, 1% Nonidet P-40, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl uoride, 10 mg/ml aprotinin, 1 mg/ml leupeptin). Equal amounts of protein (500 mg) from cell extracts were immunoprecipitated with anti-phosphotyrosine 4G10 or anti-SHP2 for 3 h. Protein A-sepharose was then added and incubated with rotation at 48C for another 2 h. Immune complexes were then washed twice with lysis buer, twice with 0.5 M LiCl in 100 mM Tris-HCl (pH 7.5) plus 100 mM sodium othovanadate, and twice with reaction buer (25 mm Tris-HCl, pH 7.5, 100 mM NaCl, 6.25 mM MgCl 2 , 0.625 mM disodium EDTA). The beads were resuspended in 40 ml of reaction buer, and 10 ml of substrate mixture (phosphatidylinositol and phosphatidylserine dispersed by sonication in 10 mM HEPES, 1 mM EGTA, pH 7.5) was added. The tubes were incubated at room temperature for 10 min and reactions were initiated by addition of 5 uCi/tube [g-32 P]ATP in 5 ul of 100 mM of ATP and terminated by addition of 80 ml of CHCl 3 :CH 3 OH(1 : 1) after another 10 min. Phospholipids were extracted, desiccated, and redissolved in 12 ul of CHCl 3 :CH 3 OH(2 : 1) and chromatographed on thin layer chromatography (TLC) plates (precoated with potassium oxalate and baked at 1008C for 1 h just before use) in CHCl 3 :CH 3 OH: 2.5 M NH 4 OH (9 : 7 : 2, v/v). Signal corresponding to phosphatidylinosital 3-phosphate (PIP) was visualized after autoradiography.
Cell growth and transformation
For cell growth, we utilized the MTT (3,(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide) assay previously described (Hansen et al., 1989; O'Rourke et al., 1997a) . For assays of focus formation of stably transfected subclones, previous methods were employed (Qian et al., 1996) .
Nuclei staining and morphologic analysis of apoptosis
Cells were plated onto coverslips for at least 12 h prior to irradiation. Dose of irradiation used for this analysis was calculated to be 10 Gray for 6 min. Coverslips were then washed twice with PBS at the indicated times, and ®xed in 50 : 50 mix of ice-cold methanol/acetone for 1 min. Coverslips were subsequently stained with 4',6-Diamidino-2-phenylindole dihydrochloride hydrate (DAPI) (Sigma, St. Louis, MO, USA) at a concentration of 0.1 ± .25 mg/ml in PBS. Interobserver consistency in apoptosis counts of DAPI-stained nuclei were con®rmed with terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-staining and by three independent observers. Statistical signi®cance of the data was determined using the Student's t-test.
Cell motility assay
Cell migration was determined as previously described (Yu et al., 1998) using modi®ed chambers containing polycarbonate membranes (tissue culture-treated, 6.5 mm diameter, 8 mm pores, transwell; Costar, Cambridge, MA, USA). The lower sides of the membrane were coated with ®bronectin (FN) (10 mg/ml) for 1 h at 378C. Trypsininized cells were ®rst washed once with DMEM containing 0.2% soybean trypsin inhibitor and then washed twice with DMEM. Cells were added to the upper chamber at 2610 4 cell/well in 100 ml of DMEM, and the lower chamber was ®lled with DMEM containing 4 mg/ml of FN. After incubation at 378C for the indicated times, the membrane was ®xed in methanol, and cells on the upper surface were mechanically removed. Migrated cells on the lower side of membranes were stained with Giemsa stain and counted under a microscope at 4006 magni®cation. Two random microscopic ®elds were counted per well, and all experiments were performed in triplicate.
Cell spreading
U87MG-derived glioblastoma cells were collected by trypsinization and washed twice with DMEM containing 0.2% soybean trypsin inhibitor (Sigma). Cell spreading was assessed as described previously (Yu et al., 1998) . Brie¯y, 2610 4 cells were resuspended in DMEM and added to the wells of 24-well plates precoated with FN (10 mg/ml) overnight at 48C. Cells were allowed to spread for the indicated times at 378C, and then photographed. Dierences in morphology were found to be easiest to quantitate at 25 min, therefore, this time point was chosen for quantitation of cell spreading.
Antibodies
Rabbit polyclonal antibodies against a GST ± SIRPa1 ectodomain (Ex1) fusion protein and against the SIRPa1 carboxyl terminus have been described previously (Kharitonenkov et al., 1997) . Anti-ERK, anti-JNK antibodies and polyclonal antibody reactive with the SHP-2 carboxyl terminus were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-SHP2 antibody used for immunoblotting and the bcl-X L polyclonal antibody were obtained from Transduction Laboratories (Lexington, KY, USA). The anti-phosphotyrosine mAb, 4G10, and the antibody reactive with the p85 regulatory subunit of PI3-K were obtained from Upstate Biotechnology (Lake Placid, NY, USA).
